Shang Hai Zheng Quan Bao·2025-08-13 18:55Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by former Vice Chairman Zuo Conglin of Beijing Zhaoyan New Drug Research Center Co., Ltd., due to personal financial needs, involving the potential sale of up to 3,524,500 shares, which represents 0.4703% of the company's total share capital [1][3]. Group 1: Shareholder Information - As of the announcement date, Zuo Conglin holds 14,098,317 shares, accounting for 1.8811% of the total share capital of the company [1]. - The shares held by Zuo Conglin originated from pre-IPO restricted shares, equity incentive shares, and shares from capital reserve conversion [1]. Group 2: Reduction Plan Details - The reduction is planned to occur between August 19, 2025, and August 29, 2025, through centralized bidding or block trading [1]. - The reduction quantity will be adjusted if there are corporate actions such as stock dividends, capital increases, or new share issuances during the reduction period [1]. - Zuo Conglin has committed to a long-term holding intention and will not sell shares below the issuance price, with adjustments for any corporate actions affecting share price [3]. Group 3: Compliance and Regulations - The reduction plan is consistent with previously disclosed commitments, and Zuo Conglin will adhere to relevant regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [3][4]. - There are no other arrangements or risks that could lead to a change in the company's control due to this reduction plan [2][4].